Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449364) titled 'Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Daewoong Group Indonesia
Condition:
Frailty in Older Adults
Intervention:
Biological: Daewoong Biologics Indonesia Umbilical Cord-derived Mesenchymal Stem Cell (DBI UC-MSC)
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: March 24, 2025
Target Sample Size: 10
Countries of Recruitment:
Indonesia
To know more, visit https://cli...